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Recent research using questionnaire measures has demonstrated high prevalence rates of
mental disorders in chronic obstructive pulmonary disease (COPD). However, clinical
interviews and clinical rather than healthy control groups have rarely been employed. The
aim of the present study was to assess mental disorders in patients with COPD with
advanced methodology, to identify moderating factors explaining mental co-morbidities
and to compare results with a clinical control group without COPD.
A standardized clinical interview (F-DIPS) and a range of questionnaires were used to
assess mental disorders, perceived physical symptoms and cognitions in 20 hospitalized
patients with mild-to-moderate COPD (mean FEV1/VC (%) ¼ 61.3). Results were compared
with a hospitalized clinical control group without pulmonary dysfunction (CCG; N ¼ 20).
Results showed that 55% of patients with COPD received a diagnosis of a mental disorder
compared to 30% of CCG patients. All principal mental diagnoses in the COPD group were
anxiety disorders (especially Panic Disorder with Agoraphobia), while CCG patients
received a wider range of diagnoses (anxiety, pain, alcohol abuse). There was no
systematic association between anxiety levels and respiratory function in the whole COPD
group, but a positive correlation between anxiety levels and perceived physical symptoms
(po0.001) as well as negative cognitions (po0.001 and po0.05, respectively) for COPD
patients with anxiety disorder (N ¼ 11).
The present results confirm the high prevalence rate of anxiety in patients with COPD and
suggest further that anxiety in COPD patients may be mediated by cognitive processes.
These findings are discussed in terms of their implications for treatment.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is a chronic
progressive condition characterized by a slowly progressive
irreversible bronchial obstruction and a fluctuating symptom
complex of recurrent productive cough and dyspnea1 and a
worldwide leading cause of morbidity and mortality.2–4 Due
to the irreversible nature of COPD, the aim of treatment in
patients with COPD is not to cure but to reduce symptoms,
increase functioning, and improve the patients’ quality of
life.1,5
It has long been suggested that emotional disturbances
such as depression and anxiety are common among patients
with COPD,6–17 which obviously has a detrimental effect on
quality of life as they affect emotional, social and physical
functioning. Recent systematic reviews reported prevalence
rates ranging from 2% to 57% for depression and 2% to 51% for
anxiety in patients with COPD.18,19 However, these and
other authors conclude that the empirical evidence for a
significant risk of depression and anxiety in this patient
group remains inconclusive because of the poor methodo-
logical quality of most of the published studies (e.g., lack of
adequate control groups, small sample sizes, variability in
instruments and cut off scores used to measure depression
and anxiety).6,18,19 Interestingly, Van Manen et al.7 found no
relationship between increased depression scores and
pulmonary function (FEV1% predicted), indicating a weak
or perhaps non-linear association between clinical measures
of pulmonary function and depressive symptoms. However,
the risk of depression was significantly increased by factors
such as living alone, perceived severity of symptoms and
self-reported impaired physical function suggesting a med-
iating role of illness perception for depressive symptoms.
It becomes clear that our knowledge about psychological
ramifications of COPD is still limited. The first issue concerns
the assessment of mental disorders in patients with COPD.
Studies have tended to use questionnaire based self-report
measures rather than clinical interviews to assess depression
and anxiety in COPD patients. For example, only 4 out of 14
studies listed in the review by Brenes19 used standard
diagnostic procedures employing DSM criteria to assess
anxiety disorders. While the use of self-report measures is
economical and allows for large samples to be screened, it is
difficult to interpret questionnaire-based results in terms of
their clinical significance for two reasons: firstly, studies
have used a variety of instruments and cut off scores to
determine the level of depression and anxiety making
comparisons between studies difficult. Secondly, question-
naire items designed to measure anxiety and depression may
overlap with symptoms that are primarily associated with
the physical symptoms of the medical condition, potentially
leading to misdiagnoses and therefore overestimations of
the prevalence rates of mental disorders in this patient
population.
A further issue concerns the question of specificity of
anxiety and depression for COPD. Depression and anxiety
have been shown to be associated with other chronic
conditions such as cardiovascular disorders, diabetes and
stroke.20 As these studies have shown it is important to
consider alternative explanations for any observed associa-
tion between mental disorders and chronic physical condi-
tions. For example, anxiety and depression may be atemporary adjustment as a result of the diagnosis of a
potentially life threatening and/or incurable disease; they
could also be the result of patients being hospitalized at the
time of investigation. However, almost all of the very few
studies which employed a controlled design used healthy
controls. Only one study15 used a random sample of geriatric
patients including those with COPD and other chronic
conditions allowing for comparisons between these groups.
However, Kvaal et al.15 only used the State–Trait Anxiety
Inventory (STAI) questionnaire to assess anxiety making it
difficult to arrive at firm conclusions about the clinical
significance of their findings.
A first aim of the current investigation was, therefore, to
address these issues by using a clinical standardized inter-
view in order to assess mental co-morbidity in hospitalized
patients diagnosed with COPD. Employing DSM-IV criteria
this interview allows for differentiation of subtypes of
mental disorders which could contribute to improvements in
treatment approaches in patients with COPD. A second aim
was to examine the specificity of any mental disorder for
COPD. Therefore, chronically ill patients who were also
hospitalized at the time of investigation but who had no
COPD related symptoms were used as a clinical control
group (CCG).
Given the previously reported elevated prevalence rates
for anxiety disorders in COPD patients it would seem
important to identify any factors explaining these findings.
Cognitive-behavioral models of anxiety and in particular
panic disorder implicate the role of catastrophic misinter-
pretations of physical sensations in the etiology and
maintenance of panic attacks.21 When patients with COPD
experience dyspnea, they may make incorrect interpreta-
tions (e.g. ‘‘I am going to die’’) in response to the feeling of
breathlessness. This in turn leads to heightened physiologi-
cal arousal, followed by additional sensations and misinter-
pretations. While breathlessness may represent actual
danger in patients with COPD, COPD patients with panic
disorder have more negative cognitions than those not
experiencing panic attacks. In previous studies, e.g.14,22 no
association could be found between anxiety levels and
objective measures of lung function impairment suggesting
that anxiety in COPD patients with panic disorder reflects
inaccurate cognitions rather than greater disease severity.
The third aim of the present study was, therefore, to
investigate any differences in agoraphobic and panic
cognitions, symptom perception and measures of pulmonary
function between COPD patients with and without anxiety
disorders.
In summary, we hypothesized that (1) there is a higher
percentage of mental disorders in hospitalized patients with
COPD compared to a hospitalized CCG, and (2) anxiety levels
in COPD patients are associated with negative cognitions
and symptom perception but not with measures of pulmon-
ary function.Methods
Participants
We examined 20 patients with mild-to-moderate COPD
(mean FEV1/VC (%) ¼ 61.3, S.D. ¼ 5.9) being hospitalized
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Table 1 Socio-demographic and medical characteris-
tics of COPD and clinical control group (CCG) patients.
COPD
(n ¼ 20)
CCG
(n ¼ 20)
p
Male gender (n) 14 (70%) 15 (75%) ns
Mean age (S.D.)
(year)
62.2 (10.0) 52.7 (13.0) 0.05
Retired (n) 13 (65%) 11 (55%) ns
Living alone (n) 3 (15%) 2 (10%) ns
Duration of primary
medical condition
(S.D.) (year)
14.1 (9.8) 9.7 (6.5) ns
FEV1/VC (%) 61.3 (5.9) – –
FEV1% predicted 75.1 (9.0) – –
C. Vo¨gele, A. von Leupoldt766at the time of investigation because of exacerbation
episodes since anxiety and depression seem to be particu-
larly prominent during periods of symptom aggravation.15,23
Eligibility criteria included age 418 years, German-speak-
ing, a clinically confirmed primary diagnosis of COPD and
patients agreement to participate. Patients were excluded
from participation if they had other co-morbid conditions
which have been shown to be associated with elevated
anxiety and depression (e.g., coronary heart disease,
stroke, cancer and dementia) and thus, would have had an
additional impact on the psychological measurements
unrelated to COPD. The CCG consisted of 20 patients being
hospitalized at the time of investigation because of
degenerative orthopaedic conditions (e.g. osteoarthritis).
Eligibility criteria were similar to those for the COPD patient
group, except that patients in this group were excluded if
any co-morbid condition with lung function impairment was
present (e.g. COPD, asthma). Study participants meeting
the inclusion criteria for the COPD or CCG were recruited
consecutively from those admitted to hospital over the
study period. Sample characteristics of the two groups are
summarized in Table 1.
Measures
Medical assessment
For both groups information on patients’ medical history was
drawn from the medical records. These data included
primary diagnosis for hospital referral, disease course and
duration, co-morbid medical conditions and current medica-
tion. In COPD patients, diagnostic status was confirmed by
lung function measurements (FEV1/VC (%), rtot) carried out
in accordance with established guidelines24 and by arterial
blood gas analyses (PaO2).
Clinical diagnostic interview (F-DIPS)
Diagnostic assessments were based on the ‘‘Diagnostisches
Interview fu¨r Psychische Sto¨rungen—Forschungsversion’’
(F-DIPS, Diagnostic Interview for Psychiatric Disorders—Re-
search Version).25 The F-DIPS is a well standardized,
validated and structured interview allowing the assessment
of mental disorders on Axis I of the DSM-IV,26 and is based onthe Anxiety Disorders Interview Schedule (ADIS-IV-L).27 DIPS
yields lifetime-, period-, and point-prevalence rates for the
following mental disorders: all anxiety disorders, all
affective disorders, hypochondrias, somatization disorder,
conversion disorder and pain disorder, substance abuse and
dependence, bulimia nervosa and anorexia nervosa. F-DIPS
interviews were conducted by a trained clinical psycholo-
gist. Written interview transcripts were scored and diag-
noses awarded by another trained psychologist who was
blind to interviewees’ medical condition.
As study participants were admitted to hospital because
of their medical condition a principal DSM-IV diagnosis was
established on the basis of individual’s assessment which
mental condition they experienced as the most stressful and
would, therefore, seek treatment for first. In addition to
current diagnoses and to extend our findings beyond
exacerbation periods, it was assessed during the interviews
whether participants met diagnostic criteria in the past
(prior history).
In an attempt to distinguish between symptoms primarily
associated with a medical condition and those occurring
during, e.g. a panic attack, patients were asked to describe
the specific circumstances in which they experienced
symptoms such as palpitations, shortness of breath, trem-
bling, feeling dizzy, sweating, fatigue, etc. Only symptoms
that were reported to occur outside exacerbation episodes
and primarily in the absence of a worsening of the medical
condition were counted towards DSM criteria. In order to
verify that reported symptoms occurred in the absence of a
worsening of the medical condition patients’ medical
records (containing physicians’ notes on when exacerbation
periods occurred) were checked against patients’ self-
report. In addition, patients’ descriptions of the specific
circumstances in which symptoms occurred were discussed
with a physician to ensure that symptoms could not be
explained in terms of COPD, e.g. by differentiating between
common physical triggers of dyspnea such as exercise or
exposure to noxious agents from common emotional triggers
such as sudden panic attacks or stress.Symptom Checklist-90-Revised (SCL-90-R)
The SCL-90-R,28 German version,29 is a well-standardized
and validated 90-item questionnaire assessing nine primary
symptom dimensions and a Global Severity Index (GSI),
based on all 90 items. Primary symptom dimensions include
somatization, obsessive–compulsive, interpersonal sensitiv-
ity, depression, anxiety, hostility, phobic anxiety, paranoid
ideation and psychoticism which refer to the preceding 6
months. The GSI is used to measure the intensity of
perceived distress. Two further main indices can be
aggregated from the SCL-90-R: positive symptom distress
(PSD), which measures the intensity of all answers and the
positive symptom total (PST), which describes the number of
above listed symptoms a person is suffering from. The SCL-
90-R is frequently used as an accompaniment to interview-
derived clinical classification providing a quantitative,
continuous measure of psychopathology.Self-Report Inventory for Somatic Symptoms (SISS)
In its original form, the SISS is a standardized and validated
paper and pencil self-report measure, which assesses the
ARTICLE IN PRESS
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the cardiovascular and gastrointestinal system.30 For the
current investigation an adapted version was used with
items added to include the musculoskeletal and respiratory
systems. Participants were asked to indicate on a scale
from 1 (not aware at all) to 7 (extremely aware) to what
extent they are frequently aware of physical sensations
(e.g. beating heart, stomach cramps, muscle tension,
airway obstruction) emanating from these body systems.
Average symptom perception scores for the four body
systems were calculated and, in addition, a total average
score was computed across all items to represent a general
measure of intensity of symptom perception.
Questionnaire on knowledge and worries about COPD
The first part of this self-constructed questionnaire was
designed to assess COPD patients’ perceived and actual
knowledge about COPD (in the interest of brevity these data
are not presented here). The second part of the ques-
tionnaire assesses worries and physical sensations when
experiencing difficulty in breathing. In particular, patients
are asked to describe the physical sensations they experi-
ence and typical thoughts occurring during an acute episode
of breathlessness in a free-response format. Interpretative
phenomenological analysis (IPA)31,32 resulted in four main
themes: fear of fear, fear of dying, staying calm, and seeking
help. For further analyses individual responses were scored
in a yes–no format depending on whether it was endorsed.
This analysis was carried out by two independent raters who
were experienced in IPA and blind to any results from the
clinical diagnostic interview. Finally, participants were
asked to indicate on a visual analogue scale33 their
subjective experience of breathlessness (‘‘how much do
you suffer from breathlessness?’’) with the anchor points
‘‘not at all’’ and ‘‘extremely’’.
Procedure
Patients in the two study groups were recruited from two
separate wards specialized in respiratory and orthopaedic
conditions, respectively, of the same medium sized district
general hospital. Patients meeting the inclusion criteria
were contacted by a trained psychologist on their hospital
ward and provided informed written consent. The interview
sessions took place after patients were stable again, i.e. on
average 4–5 days after hospital admission. At the beginning,
patients were asked to complete the self-report question-
naires and offered help with filling-in the forms if they
wished. This was followed by the clinical interview (F-DIPS).
Assessment materials were identical for both patient groups
with the exception of the questionnaire on knowledge and
worries about COPD which was administered to COPD
patients only. Those receiving a DSM-IV diagnosis were
offered referral to clinical psychological services. The study
procedure received ethical approval from the hospitals’
ethics boards.
Data analysis
Group comparisons on dichotomous data (number of
diagnoses awarded, panic/agoraphobic cognitions) werecarried out using w2-tests and Fisher’s exact test. Data on
interval scale level (SCL-90-R, SISS, pulmonary function
parameters, perceived breathlessness) were analyzed using
multivariate analysis of variance (MANOVA) with one group-
ing factor and—if significant—subsequent univariate com-
parisons between groups. Group differences in perceived
worries and physical sensations were analyzed non-parame-
trically using Mann–Whitney U-tests. For identification of
predictors of anxiety levels, a multiple regression was
performed using the anxiety scale of the SCL-90-R as
dependent variable and the total symptom perception score
of the SISS and agoraphobic/panic cognitions (fear of fear,
fear of dying) as independent variables. A significance level
of p ¼ 0.05 was applied for all statistical tests.
Results
Differences in DSM-IV diagnoses, SCL-90-R and SISS
between COPD and CCG
Table 2 gives details of current principal DSM-IV axis I
diagnoses for COPD and CCG groups by case. In addition,
current co-morbid as well as past diagnoses (‘‘prior history’’)
are listed. Only those study participants are listed who
received a current and/or past diagnosis. More than half of
all participating COPD patients (55%) received a primary
diagnosis for a mental disorder compared to 30% in the CCG
group (p ¼ 0.055). There was a significant difference
between groups in the number of patients with the principal
diagnosis ‘‘anxiety disorders’’: all of the principal diagnoses
awarded in the COPD group were anxiety disorders (n ¼ 11)
compared to four patients with anxiety disorders in the CCG
group (po0.05). The most common anxiety disorder subtype
in COPD patients was Panic Disorder with Agoraphobia (eight
out of 11 anxiety disorder diagnoses) followed by Specific
Phobia (situational type, n ¼ 2) and one case of Social
Phobia. In the CCG group there were two cases of panic
disorder with and without agoraphobia, respectively, and
one case each of Social Phobia and Specific Phobia (Blood–
Injection–Injury type). The two remaining non-anxiety
disorder diagnoses in the CCG group were one case of
Alcohol Use Disorder and one case of Pain Disorder.
Groups did not differ significantly in the number of
current co-morbid diagnoses, and the number of cases with
past diagnoses was identical between groups (n ¼ 5 each).
Although the number of past anxiety diagnoses was higher in
the COPD group (n ¼ 3) than in the CCG (n ¼ 1) this
difference was not significant. However, correlation ana-
lyses of past and current diagnoses using F as association
index revealed a significant association across the whole
sample (F ¼ 0.32, po0.05). Separate analyses performed
for each group revealed a significant association between
past and current DSM diagnoses in the COPD group only
(F ¼ 0.52, po0.05), indicating continuing psychological
symptom distress in COPD patients with a current diagnosis.
Table 3 summarizes means, S.D. and p-values for SCL-90-R
and SISS factors for both groups. MANOVA including SCL-90-R
primary symptom dimensions and SISS scales (excluding the
SCL-90-R summary scores and the SISS total symptom
perception score as they are not independent) revealed a
significant main effect for group (po0.001). Univariate
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Table 2 DSM-IV diagnoses by case for the COPD group and clinical control group (CCG) (listed are only those participants who
received a diagnosis).
Group Current principal diagnosis Current co-morbid
diagnosis
Prior history
COPD case code
1 Panic disorder with agoraphobia Generalized anxiety disorder
2 Panic disorder with agoraphobia Specific phobia
3 Panic disorder with agoraphobia Posttraumatic stress
disorder
6 Specific phobia (situational type) Generalized anxiety disorder
8 Social phobia Panic disorder without agoraphobia,
nicotine use disorder, major depressive
disorder
9 Panic disorder with agoraphobia Nicotine use disorder
14 Specific phobia (situational type) Major depressive disorder
16 Panic disorder with agoraphobia
17 Panic disorder with agoraphobia Dysthymic disorder
18 Panic disorder with agoraphobia
19 Panic disorder with agoraphobia Social phobia Nicotine use disorder, hypochondriasis
CCG case code
23 Dysthymic disorder
24 Alcohol use disorder
25 Specific phobia (blood–injection–injury
type)
26 Panic disorder with agoraphobia Specific phobia Major depressive disorder
30 Panic disorder, dysthymic disorder
32 Pain disorder
34 Major depressive disorder
38 Panic disorder without agoraphobia
39 Social phobia Major depressive disorder
C. Vo¨gele, A. von Leupoldt768comparisons of SCL-90-R factors yielded significant group
differences for somatization, depression, anxiety and phobic
anxiety, with COPD patients scoring reliably higher on these
scales than CCG participants. COPD patients also showed
two significantly higher global indices (global severity score,
positive symptom distress) and a trend for a higher positive
symptom total score, indicating higher overall psychological
symptom distress in the COPD group compared with the CCG
group. Univariate comparisons of SISS scales revealed
significantly higher scores for COPD patients on all symptom
perception scales (pp0.001) with the exception of muscu-
loskeletal symptoms, suggesting an almost uniformly more
intense perception of physical symptoms in the COPD group
compared with CCG participants. In post hoc analyses of
covariance using anxiety levels (SCL-90-R sub-scale Anxiety)
as covariate and the total symptom perception score as
dependent variable the main effect for group remained
(po0.001).Differences between COPD patients with and
without anxiety disorder
Group comparisons between COPD patients with and without
a DSM-IV diagnosis of anxiety disorder were carried out on
measures of pulmonary function, agoraphobic and panic
cognitions, symptom perception and perceived breathless-ness. Descriptive statistics and error probabilities are
summarized in Table 4. MANOVA including pulmonary
function parameters, SISS scales (excluding total symptom
perception score) and perceived breathlessness revealed a
significant main effect for group (po0.01). Univariate
comparisons produced no differences in lung function
parameters suggesting similar levels of disease severity in
COPD patients with and without anxiety disorder. However,
groups differed significantly in their perception of physical
symptoms as measured by the SISS: COPD patients with
anxiety disorder diagnosis reported higher levels of percep-
tion of cardiovascular, gastrointestinal, respiratory and
overall symptoms than COPD patients without anxiety
disorder diagnosis (all po0.001). Also, reliably more COPD
patients with anxiety disorder diagnosis reported agorapho-
bic and panic cognitions (fear of fear, fear of dying) during
an episode of acute breathlessness than those without
anxiety disorder (po0.05 and 0.001). In contrast, more
COPD patients without anxiety disorder endorsed thoughts
of ‘‘seeking help’’ during such an attack (po0.01). Groups
did not differ in their level of perceived breathlessness.
Multiple regression analyses with the anxiety scale of the
SCL-90-R as dependent variable and the total symptom
perception score of the SISS and agoraphobic/panic cogni-
tions (fear of fear, fear of dying) as independent variables
showed that anxiety levels could be predicted with a
multiple r ¼ 0.41, (po0.05).
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Table 3 Mean (S.D.) SCL-90-R and SISS results for the
COPD group and clinical control group (CCG).
COPD
(n ¼ 20)
CCG
(n ¼ 20)
p-Value
SCL-90-R
Somatisation 1.34 (0.1) 0.88 (0.4) 0.02
Obsessive–com-
pulsive
0.85 (0.5) 0.64 (0.4) 0.19
Interpersonal
sensitivity
0.46 (0.4) 0.33 (0.3) 0.28
Depression 0.76 (0.4) 0.42 (0.3) 0.01
Anxiety 0.97 (0.5) 0.38 (0.2) 0.001
Hostility 0.41 (0.3) 0.26 (0.2) 0.08
Phobic anxiety 0.57 (0.4) 0.17 (0.2) 0.001
Paranoid ideation 0.49 (0.5) 0.36 (0.4) 0.41
Psychoticism 0.25 (0.2) 0.18 (0.2) 0.34
Global severity
index
0.74 (0.3) 0.37 (0.2) 0.006
Positive symptom
distress
1.70 (0.4) 1.41 (0.2) 0.01
Positive symptom
total
37.5 (13.7) 28.6 (15.3) 0.06
SISS
Cardiovascular
symptoms
4.1 (1.1) 2.1 (0.9) 0.001
Gastrointestinal
symptoms
4.3 (1.4) 2.6 (1.4) 0.001
Musculoskeletal
symptoms
4.1 (1.7) 3.1 (1.8) 0.09
Respiratory
symptoms
4.8 (2.5) 2.25 (1.2) 0.001
Total symptom
perception
4.3 (1.0) 2.51 (0.9) 0.001
SCL-90-R, Symptom Checklist-90-Revised (range: 0–4); SISS,
Self-Report Inventory for Somatic Symptoms (range: 1–7).
Table 4 Mean (S.D.) pulmonary function, symptom
perception, agoraphobic and panic cognitions, perceived
breathlessness and perceived and actual level of COPD
information for COPD patients with and without a
principal anxiety disorder diagnosis.
COPD with
anxiety
(n ¼ 11)
COPD
without
anxiety
(n ¼ 9)
p-Value
Pulmonary function
FEV1/VC (%) 61.64 (5.9) 60.94 (6.4) ns
rtot (kPa/l/s) 0.62 (0.26) 0.67 (0.23) ns
PaO2 (mmHg) 63.78 (8.9) 64.98 (7.6) ns
SISS
Cardiovascular
symptoms
4.9 (0.7) 3.2 (0.9) o0.001
Gastrointestinal
symptoms
5.2 (0.7) 3.2 (1.2) o0.001
Musculoskeletal
symptoms
4.0 (1.6) 4.2 (1.9) ns
Respiratory
symptoms
6.0 (0.8) 3.2 (1.2) o0.001
Total symptom
perception
5.0 (0.7) 3.4 (0.7) o0.001
Agoraphobic/panic cognitions
Fear of fear Yes: 8, No: 3 Yes: 2, No: 7 o0.05
Fear of dying Yes: 10, No:
1
Yes: 0, No: 9 o0.001
Stay calm Yes: 5, No: 6 Yes: 3, No: 6 ns
Seek help Yes: 0, No:
11
Yes: 5, No: 4 o0.01
Perceived breathlessness
Visual analog scale
(0–12)
11.0 (7.7) 9.9 (2.8) ns
Information level
Perceived
(1 ¼ good,
2 ¼ medium,
3 ¼ poor)
1.6 (0.6) 1.4 (0.5) ns
Actual (range
0–14)
7.0 (3.7) 7.0 (3.5) ns
FEV1/VC (%), ratio of forced expiratory volume in 1 s to vital
capacity (%); rtot, airway resistance; PaO2, partial pressure of
arterial oxygen; SISS, Self-Report Inventory for Somatic
Symptoms (range: 1–7).
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The aims of the current study were to assess mental
disorders in hospitalized patients with COPD and to identify
moderating factors explaining any mental co-morbidity. In
contrast to most previous studies investigating mental
disorders in this patient group we used a standardized
clinical interview employing DSM-IV criteria and compared
results with a hospitalized CCG in order to test for specificity
of mental disorders in COPD. Results indicated higher overall
psychological symptom distress in COPD patients compared
with the CCG with 55% of COPD patients receiving a current
principal DSM-IV diagnoses compared to 30% in the CCG.
These findings were mirrored by the results from a
questionnaire measure (SCL-90-R). All current diagnoses in
the COPD group were anxiety disorders (n ¼ 11) which
differed significantly from the number of anxiety disorders
in the CCG (n ¼ 4). By far the most common type of anxiety
disorder in the COPD group was Panic Disorder with
Agoraphobia accounting for almost three quarters of all
(anxiety) diagnoses awarded. In contrast, not only werethere a fewer number of anxiety disorder cases in the CCG;
there was also a more heterogeneous mix of anxiety disorder
sub-types with no more than one case per diagnosis. These
elevated levels of anxiety in the COPD group were
corroborated by higher scores on the SCL-90-R sub-scales
Anxiety and Phobic Anxiety.
Our results are in line with previous studies reporting
elevated levels of anxiety disorders in patients with
COPD,6–19 with estimates ranging from 2% to 51% as outlined
in previous systematic reviews.18,19 The factors contributing
to this wide range of prevalence estimates are not clear but
most probably include differences in assessment methods,
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heterogeneity in primary medical diagnoses (COPD, Asthma
or both). With 55% the rate observed in the current study is
at the top end of this distribution. Although the small
sample size and the inclusion of patients with mild to
moderate COPD during symptom exacerbation episodes
limits any more wide-ranging conclusions about prevalence
rates of anxiety disorders in the whole population of
patients with COPD, these results indicate that anxiety
disorders in general and Panic Disorder with Agoraphobia in
particular are common among hospitalized patients with
COPD. Most importantly, the difference in the pattern of
diagnoses between the examined hospitalized patient
groups suggests that anxiety disorders are more specific to
COPD when compared with other chronic physical disorders
such as orthopaedic conditions, which already show higher
prevalence rates of anxiety disorders when compared to the
healthy population.34 Thus, the experience of a chronic
medical condition or a related hospitalization per se cannot
completely explain the high prevalence of anxiety among
these patients with COPD.
In addition to current diagnoses the clinical interview
used in the current study allowed for the retrospective
assessment of prior history of mental disorders. Although the
number of past diagnoses was identical for both groups,
there was a significant association between past and current
diagnoses in COPD patients only. In other words, those COPD
patients who had a DSM-IV diagnosis in the past were more
likely to receive a current diagnosis; this was not the case in
the CCG. This finding in combination with the obtained high
specificity of anxiety disorders in the COPD group raises the
important question of whether anxiety in COPD is a
consequence of COPD or whether anxiety can also precede
COPD and is, therefore, somehow implicated in the etiology
of this disorder. There is evidence that the lifetime
prevalence of respiratory disease is higher in people with
panic disorder compared to other mental disorders.35
Further, in a sample of 515 relatively young adults, who
had participated in the European Commission Respiratory
Health Survey (ECRHS) I and II,36,37 Neuman et al. found that
in subjects without dyspnea at the first survey the onset of
anxiety was significantly related to having dyspnea at the
second survey, i.e. 9 years later.38 In contrast, the onset of
dyspnea at the first survey was not associated with
developing anxiety at the second survey. However, due to
significant interactions with depressive symptoms and the
sole use of questionnaire measures the authors conclude
that no firm effect-relationship between psychological
status and dyspnea could be derived. The retrospective
design of the current study does not allow for the exact
establishment of the sequence of the onset of disorders.
However, the present results warrant further investigation
of the interaction of respiratory disease and anxiety
disorders.
Based on previous findings,6,7,18 we also expected
depression rates to be higher in COPD patients than in the
CGG. This was confirmed in that the former reported higher
depression scores on the relevant SCL-90-R scale compared
to the latter. However, based on the clinical interview there
were no current principal DSM-IV diagnoses of major
depression or any other mood disorder in either group
except for one case of co-morbid dysthymic disorder in theCOPD group. Van Manen et al.’s7 findings suggest a non-
linear association between depressive symptoms and mea-
sures of pulmonary function in that clinically relevant
depression scores were found only in patients with severe
airways obstruction. In addition, factors such as living alone
and self-reported impaired physical function mediated this
relationship. Lung function test results obtained for COPD
patients in the current study indicate a mild-to-moderate
level of disease severity. Taken together with the fact that
the majority of patients in the current study were living with
a partner, these differences in disease severity and living
status might explain the lack of any clinical principal
depression diagnoses. Alternatively, the use of a clinical
interview instead of questionnaire measures might have
prevented false positive diagnoses, suggesting that studies
examining the mental status in patients with COPD should
rather include diagnostic interviews than solely use ques-
tionnaires.
Our results from the SISS suggest a more intense
perception of physical symptoms in COPD patients not only
of respiratory symptoms but extending to the gastrointest-
inal and cardiovascular systems compared with CCG parti-
cipants. Because of the nature of their disease COPD
patients have ample opportunity to experience symptoms
of physiological distress. It seems noteworthy, however, that
heightened symptom perception should generalize to body
systems other than the one primarily affected by COPD, i.e.
the respiratory system. Results from the comparison of COPD
patients with and without anxiety disorder further suggest a
higher level of symptom perception in the former. This
converges with findings by Put et al.39 showing that
asthmatic patients with high negative affectivity (which
includes increased levels of anxiety) reported overall more
respiratory and other symptoms compared to patients with
low negative affectivity, which was unrelated to pulmonary
status. In psychophysiological models of anxiety and in
particular panic21 it is assumed that the more accurate and
more intense perception of cardiac activity leads to
catastrophic misinterpretations of physical symptoms and,
therefore, feeds into a vicious circle of panic (increase in
arousal, more intense perception, catastrophic misinterpre-
tation, more physical symptoms, etc). Similarly, in somati-
zation disorder a body-related perceptual style has been
described (‘‘somatic amplification’’)40 which is assumed to
be grounded on selective attention to physical symptoms.
However, whether the more accurate perception of physical
symptoms is a prerequisite for their more intense experi-
ence is unclear, and the evidence on better (i.e. more
accurate) physical symptom perception in patients with
panic disorder is inconclusive.41 Results from the current
study suggest a contributing role of physical symptom
perception to anxiety levels; however, after controlling for
the effects of anxiety levels the group difference between
COPD and CCG remained confirming the notion of a more
intense general perception of physical symptoms in patients
with COPD. Alternatively, it could be argued that individuals
who experience panic disorder are likely to experience
elevated levels of these kinds of symptoms (but not
musculoskeletal symptoms). In other words, the elevated
symptoms may not be related to the respiratory disorder,
but instead reflect the panic symptoms (perhaps even the
respiratory symptoms).
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COPD patients with anxiety disorders, the number of
patients reporting agoraphobic and panic cognitions during
an acute episode of breathlessness was higher in this group
compared with COPD patients without anxiety disorders.
These findings, in conjunction with the lack of difference in
actual respiratory function or perceived breathlessness are
consistent with the hypothesis that anxiety in COPD patients
is the result of negative cognitions and symptom perception
rather than actual or perceived respiratory distress. Similar
findings have been reported in previous studies demonstrat-
ing that health-related quality of life in COPD patients is
mostly unrelated to objective respiratory measures.42–44
This was confirmed in that anxiety levels could be predicted
by both symptom perception and negative cognitions. It is
noteworthy in this context that perceived breathlessness
(‘‘How much do you suffer from breathlessness?’’) did not
differ between anxiety groups whereas symptom perception
(‘‘To what extent are you aware of symptoms from your
lungs?’’) did. This suggests that the experience of breath-
lessness and the extent to which individuals are aware of
respiratory symptoms are independent and only the latter
contributes to anxiety. If being aware of physical symptoms
reflects the selective allocation of attention this perceptual
style would be reminiscent of ‘‘somatic amplification’’33 as
described for somatization disorder.
More than half of COPD patients without anxiety disorder
reported thoughts of seeking help during an acute episode of
breathlessness as opposed to none in those with anxiety
disorder. This seems to indicate that ‘‘seeking help’’ may
be a positive cognitive or behavioral coping strategy possibly
leading to an increased sense of control and, therefore,
preventing increases in anxiety and catastrophic misinter-
pretations of physical symptoms. However, these results
should be considered as preliminary and, therefore, in need
of replication in future research as the questionnaire
used was self-constructed with yet unknown psychometric
properties.Clinical implications
Recent reports have emphasized the role of mental factors
on the course of disease in respiratory disorders.12,13,45 In
particular anxiety and negative affectivity have been
suggested to be associated with inadequate medication
use,46 frequent visits to the physician,47 increased number
and duration of hospitalizations,23,48 patients’ treatment
preferences49 as well as increased mortality, symptom
burden, and poorer physical and social functioning.48 The
findings of the current study have, therefore, implications
for interventions designed to reduce symptoms, increase
functioning, and improve COPD patients’ quality of life. First
and foremost, our results with improved methodology
confirm that anxiety disorders are common among hospita-
lized patients with COPD, thus, underlining the importance
of screening for mental disorders in this patient group. By
far the most common anxiety disorder in the current study
was Panic Disorder with Agoraphobia. The treatment
procedure of choice for Panic Disorder with Agoraphobia is
cognitive-behavioral treatment which typically involves
cognitive restructuring, interoceptive exposure and re-peated confrontation with, or approach to, the object or
situation that is avoided. Given the evidence for the efficacy
of exposure-based treatments,50 it is tempting to conclude
that this approach should also be used in the treatment of
anxiety disorders in COPD patients. However, cognitive
restructuring will have to strike a very tenuous balance
between proper monitoring of physical symptoms that could
signal actual danger while reducing catastrophic misinter-
pretation of benign physical sensations. It should be noted in
this context that this problem is not unique to COPD but
applies also to other chronic conditions, e.g. chronic pain.
Perhaps helpful in finding this equilibrium between appro-
priate monitoring and hypervigilance while also improving
mobility could be targeting the agoraphobic avoidance that
seems to be prevalent among anxiety disordered COPD
patients. Agoraphobic avoidance is specified in the DSM-IV
nosology as avoidance, or endurance with distress, of
situations from which escape might be difficult or in which
help is unavailable in the event of a panic attack or of
developing symptoms that could be incapacitating or
embarrassing.26 Typical situations that are avoided include
shopping in malls, waiting in lines, attending movie
theatres, traveling by car or bus, visiting crowded restau-
rants and stores, and being alone. Successful reduction of
agoraphobic avoidance through exposure techniques would
almost certainly lead to the mobilization of anxiety
disordered COPD patients thus increasing their physical
activity. High levels of physical activity, in turn, have been
shown to be associated with a 46% reduction in the risk of
hospital readmission in COPD patients.51 First encouraging
findings were recently reported by Kunik et al.52 suggesting
that as little as two hours of group therapy containing
elements of cognitive-behavioral therapy can lead to a
reduction of symptoms of depression and anxiety compared
to a control group who only received patient education.
However, future studies with randomized controlled designs
and longer-lasting programs are necessary to testify the
effects of cognitive-behavioral treatments for reducing
anxiety as well as improving symptom management in
patients with COPD.53,54Limitations of the current study
Besides the limited sample size and the exclusive investiga-
tion of patients with mild-to-moderate COPD admitted to
hospital because of exacerbation episodes, it cannot be
ruled out that the age difference between our study groups
may have impacted on the results. However, it seems
unlikely that the higher number of anxiety disorder
diagnoses in the COPD group could be explained by the
older age in this group, as the main age of onset for Panic
Disorder with Agoraphobia lies between adolescence and the
mid-30s. Any age-related increase in prevalence should have
occurred before the mean age of the current two groups.
This view was supported by an additional set of analyses
including age (and also gender) as covariates, which yielded
no meaningful differences to the reported results. Moreover,
patients with co-morbid conditions (e.g., coronary heart
disease, stroke, dementia) were excluded, because these
conditions have been shown to be associated with increased
levels of anxiety and depression, which could have added to
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coronary heart disease is common in patients with COPD
this exclusion could somewhat limit the generalizability
of our results. Further, we cannot completely rule out
that some of the psychological symptoms in the patients
history occurred during exacerbation periods, e.g. due to
incomplete medical charts. However, this seems rather
unlikely due to the careful assessment of these prior
symptoms in a threefold way: by interview, by crosschecking
the medical records and by discussing all symptoms with a
physician.
In addition, the design of the study does not allow for
cause and effect relationships between COPD and mental
disorders to be firmly established. While it appears that
symptom perception and catastrophic interpretations of
bodily symptoms play a role in the onset of anxiety
symptoms in COPD, this cannot be conclusively stated due
to the retrospective nature of the current study design.
Future investigations of etiologically relevant factors will,
therefore, benefit from well-controlled prospective designs.Conflict of interest statement
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